Portal hypertension can arise from any condition interfering with normal blood flow at any level within the portal system. Herein, we presented two uncommon cases of the portal hypertension and its treatment with brief literature review. A 71-year-old man who underwent right hemihepatectomy revealed a tumor recurrence adjacent to the inferior vena cava (IVC). After radiofrequency ablation (RFA) with lymph node dissection, he was referred for abdominal distension. The abdomen computed tomography scan showed severe ascites with a narrowing middle hepatic vein (MHV) and IVC around the RFA site. After insertion of two stents at the IVC and MHV, the ascites disappeared. Another 73-year-old man underwent right trisectionectomy of liver and segmental resection of the portal vein (PV). After operation, he underwent conservative management due to continuous abdominal ascites. The abdomen computed tomography scan showed severe ascites with obliteration of the left PV. After insertion of stent, the ascites disappeared. A decrease of the pressure gradient between the PV and IVC is one of the important treatment strategies for portal hypertension. Vascular stent is useful in the reduction of pressure gradient and thus, can be a treatment option for portal hypertension. 
INTRODUCTION
Portal hypertension is a common clinical syndrome that is characterized by an increased portal pressure gradient.
It causes an increased pressure gradient between the portal vein (PV) and the inferior vena cava (IVC) to above normal values (1) (2) (3) (4) (5) . Portal hypertension causes varices within the gastrointestinal tract and can lead to gastrointestinal bleeding with abdominal ascites, diffuse abdominal pain, diarrhea and hepatic dysfunction. [1] [2] [3] Chronic liver disease is the most common cause of portal hypertension. 1 However, portal hypertension has various rare causes. 2 Herein, we presented two uncommon cases of the portal hypertension and its treatment with a brief literature review.
CASE

Case 1
A 71-year-old man who underwent right hemihepatectomy one year prior due to combined hepatocellular and cholangiocarcinoma was found with elevated CA19-9 level of 60.2 U/ml at the follow-up examination. The imaging studies revealed tumor recurrence in the resection margin that was adjacent to the inferior vena cava (IVC) with an enlarged metastatic lymph node (LN) at the hepatoduodenal area. We performed radiofrequency ablation (RFA) with LN dissection due to severe adhesion between the tumor and IVC.
Pathologic examination confirmed metastatic carcinoma derived from the previous cancerous lesion. Two weeks after discharge, he was referred to the emergency room for abdominal distension. Laboratory tests showed hypoalbuminemia (2.7 g/dl) and prolonged prothrombin time luminal compression. 4 Hepatic vein occlusion after radiofrequency ablation is classified as secondary BCS and its incidence is very rare. Hepatic vein occlusion occurs by liver parenchymal deformity due to hepatic infarction.
However, the reported incidence of hepatic infarction after RFA is only 0.1%. 6 Moreover, because of the heat-sink effect that is due to the adjacent hepatic vessels, hepatic infarction rarely occurs around hepatic vein. 7 Portal venous stenosis by extrahepatic obstruction accounts for 5-10% of portal hypertension. 8 Increasing liver transplantation has led to frequent cases of acquired portal vein stenosis post-transplantation. 9 In the non-transplant population, PV stenosis occurs rarely due to tumor encasement or post-surgical complications. 10 While PV stenosis was manifested in advanced pancreatic and biliary neoplasms a decade ago, it currently presents as post-surgical complications.
10,11
Although portal hypertension is derived from different causes, it causes similar and typical symptoms such as as- There is currently no consensus on prophylactic anticoagulation therapy for maintaining stent patency after its insertion for portal hypertension. Some recommend at least 6 month interval follow-ups for clinical and laboratory evaluations. 2 Our patients were treated with warfarin and evaluated for stent patency using abdomen CT scans every 3 months; consequently, the first stent has been patent for 8 months and the other stent for 6 months.
In conclusion, regardless of the causes, a decrease of the pressure gradient between the PV and the IVC is one of the important treatment strategies of portal hypertension. Vascular stent is useful to reduce the portal pressure gradient and thus, can be a treatment option for portal hypertension.
